Publications in VIVO

Co-author Network

Co-investigator Network

Charles Windon, MD

Person

Positions

Assistant Professor, University of California, San Francisco

Clinical Disciplines

Neurology

Publications
Research
Other
View All

Selected Publications

article
1. Calibration of multisite raters for prospective visual reads of amyloid PET scans.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 21:-. 2025
2. Concordance Between Amyloid-PET Quantification and Real-World Visual Reads.. JAMA neurology. 82:952-962. 2025
3. Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 21:-. 2025
4. Sex differences in amyloid PET in a large, real-world sample from the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 21:-. 2025
5. Positive Childhood Experiences, Cognition, and Biomarkers of Alzheimer's Disease.. International journal of environmental research and public health. 22. 2025
6. Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.. Annals of neurology. 98:236-248. 2025
7. Navigating barriers to dementia specialty care among vulnerable populations: Insight from a multidiscipline care navigation team.. Journal of Alzheimer's disease reports. -. 2025
8. Predicting the progression of MCI and Alzheimer’s disease on structural brain integrity and other features with machine learning. GeroScience. 2025
9. Perceptions about dementia clinical trials among underrepresented populations: a nationally representative survey of U.S. dementia caregivers.. Alzheimer's research & therapy. 16:-. 2024
10. Perceptions about dementia clinical trials among underrepresented populations: A nationally representative survey of U.S. dementia caregivers.. Research square. 2024
11. Promoting Growth in Behavioral Neurology: A Path Forward.. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. 37:49-56. 2024
12. Underrepresented and Underserved Populations in Neurological Research.. Seminars in neurology. 44:168-177. 2024
13. Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 20:2089-2101. 2024
14. A clock model of regional tau‐PET accumulation and cognitive decline in sporadic early‐onset Alzheimer's disease. Alzheimer's & Dementia. 2024
15. A clock model of regional tau‐PET accumulation and cognitive decline in sporadic early‐onset Alzheimer’s disease. Alzheimer's & Dementia. 2024
16. Amyloid‐PET in patients with a clinical diagnosis of sporadic early‐ versus late‐onset AD: comparison of the LEADS and ADNI cohorts. Alzheimer's & Dementia. 2024
17. Amyloid‐PET in patients with a clinical diagnosis of sporadic early‐ versus late‐onset AD: comparison of the LEADS and ADNI cohorts. Alzheimer's & Dementia. 2024
18. Association Between Late‐Life Depression and Amyloid Beta Burden in Older Adults Without Cognitive Impairment: A. Systematic Review and Meta‐Analysis. Alzheimer's & Dementia. 2024
19. Characterization of the heterogeneity of amyloid‐PET‐negative patients with a clinical diagnosis of sporadic early‐onset AD: an FDG‐PET study in the LEADS cohort. Alzheimer's & Dementia. 2024
20. Characterization of the heterogeneity of amyloid‐PET‐negative patients with a clinical diagnosis of sporadic early‐onset AD: an FDG‐PET study in the LEADS cohort. Alzheimer's & Dementia. 2024
21. Childhood adversity predicts worse verbal and visual memory in cognitively intact older White and Latino adults in California. Alzheimer's & Dementia. 2024
22. Clinical Impact of Amyloid PET in Diverse Medicare Beneficiaries with Cognitive Impairment: Preliminary Results from New IDEAS. Alzheimer's & Dementia. 2024
23. Implementation of Blood‐based Biomarkers in a Large Dementia Care Clinic: Case‐based Report from the UCSF Memory and Aging Center. Alzheimer's & Dementia. 2024
24. Learning from Real‐World Data Platforms: Insights into Care and Representation in Research Through ALZ‐NET and New IDEAS. Alzheimer's & Dementia. 2024
25. Promoting Growth in Behavioral Neurology: A Path Forward. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology. 2024
26. Residential Neighborhood Disadvantage and Amyloid Positivity: Findings from IDEAS. Alzheimer's & Dementia. 2024
27. Residential Neighborhood Disadvantage and Amyloid Positivity: Findings from IDEAS. Alzheimer's & Dementia. 2024
28. Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias. Alzheimer's & Dementia. 2024
29. Sex Differences in Amyloid PET in a Large, Real‐Life Sample from the Imaging Dementia‐Evidence for Amyloid Scanning (IDEAS) Study. Alzheimer's & Dementia. 2024
30. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).. Alzheimer's & dementia : the journal of the Alzheimer's Association. 19 Suppl 9:S98-S114. 2023
31. 64 Neuroimaging Evidence of Neurodegenerative Disease in Former Professional American Football Players Who “Fail” Validity Testing: A Case Series. Journal of the International Neuropsychological Society : JINS. 2023
32. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer′s Disease Study (LEADS). Alzheimer's & Dementia. 2023
33. Amyloid‐, tau‐, and FDG‐PET in amyloid‐negative patients clinically diagnosed with early‐onset Alzheimer’s disease in the LEADS study. Alzheimer's & Dementia. 2023
34. Amyloid‐, tau‐, and FDG‐PET in amyloid‐negative patients clinically diagnosed with early‐onset Alzheimer’s disease in the LEADS study. Alzheimer's & Dementia. 2023
35. Amyloid‐PET, tau‐PET, and their association in sporadic early‐onset Alzheimer’s Disease: Cross‐sectional and longitudinal data from the LEADS study. Alzheimer's & Dementia. 2023
36. Comparison of Expert Reads vs. Local Clinical Reads of Amyloid PET Scans in IDEAS. Alzheimer's & Dementia. 2023
37. Comparison of Expert Reads vs. Local Clinical Reads of Amyloid PET Scans in IDEAS. Alzheimer's & Dementia. 2023
38. Perceptions about Dementia Clinical Trials. Alzheimer's & Dementia. 2023
39. Quantitative Amyloid‐PET in Real‐World Practice: Lessons from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study. Alzheimer's & Dementia. 2023
40. Regional patterns of pathological tau accumulation in sporadic early‐onset Alzheimer’s disease: Longitudinal tau‐PET in the LEADS Cohort. Alzheimer's & Dementia. 2023
41. Towards the future of ADRD diagnosis: combination of a brief digital cognitive battery and plasma biomarkers for diagnosis and prognosis of disease. Alzheimer's & Dementia. 2023
42. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study.. JAMA neurology. 79:1139-47. 2022
43. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI.. Alzheimer's & dementia (Amsterdam, Netherlands). 14:-. 2022
44. 18F‐MK‐6240 Tau PET as a Biomarker for Chronic Traumatic Encephalopathy: Case Series of 10 Symptomatic Former National Football League Players. Alzheimer's & Dementia. 2022
45. Amyloid Negative, Highly Tau Positive: Clinical Characterization of a Rare Biomarker Profile. Alzheimer's & Dementia. 2022
46. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2022
47. Quantitative analysis of 6,150 real‐world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) study. Alzheimer's & Dementia. 2022
48. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study. JAMA Neurology. 2022
49. Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California.. JAMA neurology. 78:657-665. 2021
50. Perils of Race-Based Norms in Cognitive Testing: The Case of Former NFL Players.. JAMA neurology. 78:377-378. 2021
51. Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults.. Brain imaging and behavior. 15:2417-2425. 2021
52. Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California. JAMA Neurology. 2021
53. Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults. Brain Imaging and Behavior. 2021
54. Comparison of plasma and CSF biomarkers across ethnoracial groups in ADNI. Alzheimer's & Dementia. 2021
55. IDEAS and New IDEAS: Amyloid PET in diverse populations. Alzheimer's & Dementia. 2021
56. Perils of Race-Based Norms in Cognitive Testing The Case of Former NFL Players. JAMA Neurology. 2021
57. Rapid Revascularization of Simultaneous Bilateral ICA Occlusions causing Coma. Neurology. 2018
58. Neuropeptide VGF Promotes Maturation of Hippocampal Dendrites That Is Reduced by Single Nucleotide Polymorphisms. International Journal of Molecular Sciences. 2017
59. Neuropeptide VGF Promotes Maturation of Hippocampal Dendrites That Is Reduced by Single Nucleotide Polymorphisms. International journal of molecular sciences. 18:612. 2017
60. The Antidepressant-Like Agent Neuropeptide VGF: Mechanism of Action on Adult Neurogenesis and Effect of SNPs on Expression Levels. Biological Psychiatry. 2014
61. Redefining Human Vitamin D Sufficiency: Back to the Basics. Bone Research. 2013
62. Redefining Human Vitamin D Sufficiency: Back to the Basics. Bone research. 1:2-10. 2013
document
1. Concordance between amyloid-PET quantification and real-world visual reads: results from IDEAS 2024
2. Vascular Cognitive Impairment 2024
3. Rapid Revascularization of Simultaneous Bilateral ICA Occlusions causing Coma. Neurology. 2018
4. The Antidepressant-Like Agent Neuropeptide VGF: Mechanism of Action on Adult Neurogenesis and Effect of SNPs on Expression Levels. Biological psychiatry. 2014